V.le Fulvio Testi, 330
Italfarmaco SpA is a private Italian multinational company located in Milan, operating in Italy and abroad in both the pharmaceutical and fine chemical industries through its controlled and/or participated companies.
6 articles with Italfarmaco
Italfarmaco Group Enters Into an Agreement with Luye Pharma to Commercialize Alzheimer’s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Four European Countries
Italfarmaco Group adds innovative Alzheimer’s disease therapy to its neurology-based product portfolio
Italfarmaco Provides Update on Ongoing Clinical Programs with Givinostat in Oral Presentation at XVIII International Conference on Duchenne and Becker Muscular Dystrophy
Analyses of long-term study with Givinostat in Duchenne Muscular Dystrophy boys continue to show delayed disease progression
Italfarmaco Receives FDA Rare Pediatric Disease Designation for Givinostat in Duchenne Muscular Dystrophy, Announces Completed Enrollment in EPIDYS Phase 3 Trial
The Italfarmaco Group provided an update on the development of Givinostat, its proprietary histone deacetylase inhibitor, in boys with Duchenne Muscular Dystrophy.
Italfarmaco Provides Update on Advanced-Stage Clinical Development Program with Givinostat in Duchenne Muscular Dystrophy
The Italfarmaco Group provided an update on the clinical development program of Givinostat, its proprietary histone deacetylase inhibitor, in Duchenne Muscular Dystrophy.
Italfarmaco Enters Binding Term Sheet Agreement With Neupharma for an Exclusive Option to Develop and Commercialize Inhaled Teicoplanin
Italfarmaco Group announced that Italfarmaco SpA, a member company, has entered into a binding term sheet agreement with Neupharma for an exclusive option to develop and commercialize inhaled teicoplanin.
Italfarmaco has its eyes set on bringing a new treatment that targets the underlying mechanism of the blood disorder Polycythemia Vera.